Bromide

Bromide

SCHEMBL4524176

Br.CCOC(=O)C[PH](c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GAA P10253 1/20 0.45
TSHR P16473 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
PIN1 Q13526 2/20 0.44
PPID Q08752 1/20 0.43
ALDH1A1 P00352 2/20 0.42
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
ABCB1 P08183 1/20 0.40
PTPN1 P18031 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL65904 0.98 MEN1 (0.47) MEN1KMT2AGAATSHRSMN1; SMN2
Hydrochloric Acid SCHEMBL28051579 0.96 MEN1 (0.46) MEN1KMT2AGAATSHRSMN1; SMN2
Hydrochloric Acid SCHEMBL29226981 0.96 MEN1 (0.46) MEN1KMT2AGAATSHRSMN1; SMN2
SCHEMBL7770716 0.85 GAA (0.44) MEN1KMT2AGAATSHRSMN1; SMN2
SCHEMBL3640178 0.83 ALDH1A1 (0.42) MEN1KMT2AGAATSHRSMN1; SMN2
Bromide SCHEMBL10944555 0.83 SMN1; SMN2 (0.49) MEN1KMT2ATSHRSMN1; SMN2ALDH1A1
SCHEMBL3633415 0.82 ALDH1A1 (0.38) KMT2AGAATSHRPIN1ALDH1A1
Bromide SCHEMBL29024015 0.81 POLB (0.44) TSHRSMN1; SMN2ALDH1A1NPC1
SCHEMBL14394283 0.81 TSHR (0.51) MEN1KMT2AGAATSHRSMN1; SMN2
SCHEMBL21260456 0.81 MEN1 (0.49) MEN1KMT2AGAATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111592477-A Novel intermediate compound for preparing norbixin or bixin ethyl ester and preparation method thereof 明知大学校产学协力团 2020-08-28 CN claimed
CN-108033902-A A kind of preparation method of his cis-isomer of high-purity Baily department 深圳万乐药业有限公司 2018-05-15 CN claimed
CN-105367455-B A kind of preparation method of his isomers of Baily department 深圳万乐药业有限公司 2017-10-24 CN claimed
CN-105367455-A Preparation method of Belinostat isomer SHENZHEN MAIN LUCK PHARMACEUTICALS INC 2016-03-02 CN claimed
CN-117736241-B Organic-inorganic hybrid perovskite glass material capable of emitting light through long afterglow phosphorescence and preparation method thereof 北京师范大学 2026-05-15 CN disclosed
CN-120554416-A Multimode response manganese-based halide luminescent material, and preparation method and application thereof 武汉纺织大学 2025-08-29 CN disclosed
CN-117736241-A Organic-inorganic hybrid perovskite glass material capable of emitting light through long afterglow phosphorescence and preparation method thereof 北京师范大学 2024-03-22 CN disclosed
CN-117177977-A Bicyclic pyridine derivatives 住友制药株式会社 2023-12-05 CN disclosed
CN-113461602-B Aniline compounds with HDAC (Histone deacetylase) inhibitory activity, preparation method, composition and application 北京华氏信华科生物科技有限公司 2022-06-28 CN disclosed
CN-111592477-A Novel intermediate compound for preparing norbixin or bixin ethyl ester and preparation method thereof 明知大学校产学协力团 2020-08-28 CN disclosed
CN-106414434-B Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes 詹森药业有限公司 2019-12-31 CN disclosed
CN-108033902-A A kind of preparation method of his cis-isomer of high-purity Baily department 深圳万乐药业有限公司 2018-05-15 CN disclosed
CN-105367455-B A kind of preparation method of his isomers of Baily department 深圳万乐药业有限公司 2017-10-24 CN disclosed
CN-105646439-A Synergist for antifungal drugs, and preparation and application thereof 中国人民解放军第二军医大学 2016-06-08 CN disclosed
CN-105367455-A Preparation method of Belinostat isomer SHENZHEN MAIN LUCK PHARMACEUTICALS INC 2016-03-02 CN disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 MEN1 1254/4885KMT2A 2379/4885GAA 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.